arrow
K

Kimberly C. Claeys

university of maryland baltimore
H指数:27
被引数:2,331

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis

厄他培南治疗肠球菌感染的临床疗效与安全性:一项亚人群分析

2025-12-290
OAAI
Evaluation of cefazolin <3 g vs. 3 g treatment doses for cellulitis in patients who weigh≥120 kg within a large, community health system via modified desirability of outcomes ranking (DOOR) methodology

Gens, K.D.; Gagnon, B.R.; Claeys, K.C.; Wankum, M.A.; Hirsch, E.B. 通过改良的结局可取性排序(DOOR)方法学,在大型社区健康系统中评估头孢唑林<3 g与3 g治疗剂量对体重≥120 kg患者的蜂窝织炎的疗效。J. Infect. Chemother. 2025, 31, 102833. [Google Scholar] [CrossRef]

2025-11-011
PRE
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers

实施诊断 stewardship 以改善3家医疗中心泌尿道感染抗生素的使用

2025-08-011
PRE
Evaluating antimicrobial stewardship strategies in candidemia: a novel desirability of outcome ranking (DOOR) analysis comparing blood culture versus T2Candida diagnostic approaches

评估念珠菌血症中的抗菌药物管理策略:一项比较血培养与T2Candida诊断方法的新型预期结果排名(DOOR)分析

2025-05-140
OA
Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 US regions from 2018 to 2022

Eravacycline,前四年: 2022年2018年美国5个地区19家医院的健康结果和耐受性数据

2024-01-119
OAAI
Real-world Antimicrobial Stewardship Experience in a Large Academic Medical Center: Using Statistical and Machine Learning Approaches to Identify Intervention Hotspots in an Antibiotic Audit and Feedback Program

大型学术医疗中心的真实世界抗菌药物管理经验: 使用统计和机器学习方法确定抗生素审核和反馈计划中的干预热点

2022-06-1014
OAAI